Get the Stockscreener App
26.71
0.19%
0.05
After Hours:
26.69
-0.02
-0.07%
Kalvista Pharmaceuticals Inc stock is traded at $26.71, with a volume of 5.32M.
It is up +0.19% in the last 24 hours and up +34.22% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$26.66
Open:
$26.67
24h Volume:
5.32M
Relative Volume:
2.19
Market Cap:
$1.42B
Revenue:
$75.04M
Net Income/Loss:
$-167.18M
P/E Ratio:
-8.3555
EPS:
-3.1967
Net Cash Flow:
$-168.39M
1W Performance:
+38.83%
1M Performance:
+34.22%
6M Performance:
+143.04%
1Y Performance:
+103.89%
1-Day Range:
$26.66
$26.72
1-Week Range:
$26.63
$26.76
52-Week Range:
$9.83
$26.76
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
26.71 | 1.42B | 75.04M | -167.18M | -168.39M | -3.1967 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Reiterated | Needham | Buy |
| Jan-06-26 | Reiterated | Needham | Buy |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
Chiesi Farmaceutici (NASDAQ: KALV) offers $27.00 per share to buy KalVista - Stock Titan
KalVista climbs as Italy’s Chiesi agrees to acquire in $1.9B deal - MSN
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? - Sahm
Chiesi to buy KalVista Pharmaceuticals for $1.9 billion - MSN
Avoiding Lag: Real-Time Signals in (KALV) Movement - Stock Traders Daily
HC Wainwright & Co. downgrades KalVista Pharmaceuticals (KALV) - MSN
KalVista Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Millennium group reports shared control of 1.9M KalVista shares (KALV) - Stock Titan
KALV Downgraded by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
KalVista Pharmaceuticals 2025 Executive Compensation, Equity Awards, and Corporate Governance Highlights - Minichart
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc.KALV - Business Wire
H.C. Wainwright Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating, Cuts Target Price to $27 - Moomoo
KalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to "Neutral" at HC Wainwright - MarketBeat
Kalvista Pharmaceuticals stock rating cut to neutral by H.C. Wainwright on merger deal - Investing.com Nigeria
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Rating Lowered by JonesTrading - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Downgraded by Leerink Partners to Hold - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Downgraded by Citizens Jmp to Hold - MarketBeat
Needham Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating - Moomoo
KalVista Pharmaceuticals | 10-KT/A: Others - Moomoo
IBT portfolio manager says KalVista deal signals Biotech 2.0 growth - Proactive financial news
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout - MSN
KalVista (NASDAQ: KALV) amends 10-KT, reveals April 29, 2026 merger deal with Chiesi - Stock Titan
KALV Downgraded by Needham -- Rating Changed to Hold - GuruFocus
KalVista Pharmaceuticals (NASDAQ:KALV) Given "Hold" Rating at Needham & Company LLC - MarketBeat
Hereditary Angioedema Market: Rapid Increment Driven by Innovation by 2034DelveInsight - openPR.com
KalVista Pharmaceuticals (NASDAQ:KALV) Sees Large Volume IncreaseHere's Why - MarketBeat
Chiesi commits $1.9bn to rare disease expansion with KalVista Buy - BioXconomy
Jones Trading downgrades Kalvista stock to hold on Chiesi acquisition By Investing.com - Investing.com South Africa
Jones Trading downgrades Kalvista stock to hold on Chiesi acquisition - Investing.com
Italy: Chiesi Group expanding global Rare Disease portfolio with US$1.9bn acquisition of KalVista - Investors in Healthcare
Shorted-to-The-Hilt KalVista Rockets 39% as Chiesi Swoops in With $1.9bn Cash Bid - NAI500
Leerink Partners Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating, Announces Target Price $27 - Moomoo
KalVista Downgraded to $27 Target as Chiesi’s All-Cash Takeout Caps Near-Term Upside, Supporting Hold Rating - TipRanks
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio - 투데이안
JonesTrading Downgrades KalVista Pharmaceuticals(KALV.US) to Hold Rating, Cuts Target Price to $27 - Moomoo
DRI Healthcare Trust Evaluates Royalty Agreement With KalVista After Chiesi Deal Proposal - Moomoo
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement - The Motley Fool
KalVista Pharmaceuticals | SC14D9C: Written communication by the subject company relating to a third party tender offermoomoo - Moomoo
Chiesi Grows Again In Rare Diseases With Its Largest Deal Yet, Buying KalVista - Citeline News & Insights
Sector Update: Health Care Stocks Fall Late Afternoon - Moomoo
Chiesi to acquire KalVista Pharmaceuticals for $1.9 billion By Investing.com - Investing.com Australia
DRI Healthcare Trust Comments on Proposed Acquisition of KalVista Therapeutics, Inc. - Newswire Canada
Biotech Scores $1.9 Billion Deal; Why A Key Rival Also Jumped - Investor's Business Daily
Deal And Earnings Wins Powered A Big Day For Three Stocks - Finimize
Italian drugmaker Chiesi to buy KalVista for $1.9 billion - Classic Rock 103.5 WIMZ
CPI | Italian Drugmaker to Buy KalVista for $1.9 Billion - PYMNTS.com
Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition - MedCity News
KalVista (KALV) Receives No Rating Following Acquisition Announcement - GuruFocus
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement - TradingKey
KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
KalVista moved to No Rating at BofA - TipRanks
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):